ModifiedUnitedHealthcarePolicy CS198ID.B

Chemotherapy Observation or Inpatient Hospitalization (for Idaho Only)

Defines when chemotherapy administration requires an inpatient hospital stay versus observation for UnitedHealthcare members in Idaho (including Idaho Medicaid Plus), listing specific regimens, cancer types, and clinical factors that necessitate inpatient care; other cases reviewed case-by-case referencing InterQual LOC.

Policy Summary

PayerUnitedHealthcare

PolicyChemotherapy Observation or Inpatient Hospitalization (for Idaho Only)

Policy CodePolicy CS198ID.B

Change TypeRemoved pediatric exclusion; updated clinical evidence

Effective DateMay 1, 2026

Next Review Date

Key ActionA written protocol must be followed by the provider administering the chemotherapy drug.

SourceLink

POLICY UPDATE CHANGES

Removed language indicating this policy does not apply to individuals under 18 years of age.

Updated Clinical Evidence and References sections to reflect current information.

MultipleRegimens explicitly requiring inpatient stay

IdahoGeographic scope

1Policy document identifier

Coverage Summary

This policy addresses when chemotherapy administration requires an inpatient hospital stay versus an observation stay for UnitedHealthcare members in Idaho (including Idaho Medicaid Plus). The stance is mixed: most regimens can be given outpatient or at home, but specific regimens, patient comorbidities, or needs for close physiologic monitoring may necessitate inpatient admission.

Policy metadata

policy_numberCS198ID.B

effective_dateMay 1, 2026

last_reviewMay 1, 2026

geographic_scopeIdaho-only (includes Idaho Medicaid Plus)

policy_document_identifier1

Inpatient hospital stay is medically necessary for drug regimens that require inpatient monitoring or complex administration over multiple days. The policy lists specific regimen- and condition-specific elements (for example, multi-day continuous infusions, coordination of multiple infusions over 96 hours, need for continuous cardiac or electrolyte monitoring, or close monitoring of serum drug levels) that, when ALL apply, indicate an inpatient stay is required.

Medical Necessity Criteria: Inpatient, Observation, and Case-by-case

Clinical conditions which require an inpatient hospital stay (listed)

The following specific clinical conditions require inpatient hospitalization:

ANY of the following

Acute leukemia
Intra-arterial infusion of chemotherapy
Prophylaxis of tumor lysis syndrome in cases of high-grade lymphoma with large masses

Observation stay may be appropriate

The following are clinical conditions or complications which may require an observation stay (provider expected to follow a written protocol):

Clinical conditions or complications of cancer chemotherapy that may require observation (general statement; see regimen-specific factors above for inpatient criteria)

Key thresholds

Methotrexate serum level thresholds for leucovorin escalation> 20 µmol/L at 0 hour; > 1.0 µmol/L at 24 hours; > 0.1 µmol/L at 48 hours (increase leucovorin to 50 mg IV every 6 hours until levels < 0.1 µmol/L)

Ifosfamide high-dose threshold> 1 g/m2/day

Etoposide infusion duration for EPOCH regimens50 mg/m2/day continuous infusion days 1-4 (EPOCH); 40 mg/m2/day continuous infusion days 1-4 (ESHAP)

Provider Actions and Requirements

Documentation Required

Written protocol required

A written protocol must be followed by the provider administering the chemotherapy drug.

Prior Authorization

Extension of inpatient stay

Any requests for an extension of the inpatient stay beyond the recommended day(s) must be clinically reviewed.

Documentation Required

Refer to InterQual for medical necessity determinations

For cases not explicitly listed, medical necessity clinical coverage criteria will be reviewed and determined using InterQual LOC: Acute Adult Hematology/Oncology — specifically the InterQual LOC: Acute Adult, Hematology/Oncology: Complications or Disease Progression and InterQual LOC: Acute Adult Hematology/Oncology: Treatments modules.

Policy Identifiers and Codes

Policy identifiersmixed

CS198ID.B

UnitedHealthcare policy number (current archived version)

No CPT/HCPCS/ICD billing codes are provided in the brief. Coding for inpatient versus observation billing should follow the facility’s billing guidance and any InterQual determinations used for level-of-care review.

Background and Clinical Evidence

Rationale: Most chemotherapies can be delivered safely in outpatient clinics or at home, but certain regimens and clinical scenarios require inpatient care because they need complex multi-day administration or close physiologic monitoring (for example continuous infusions, intensive electrolyte or urine pH management, methotrexate level monitoring, or vasopressor support). The policy references evidence showing outpatient feasibility for selected regimens while recognizing risks that prompt admission. It cites the ASCO-ONS 2024 antineoplastic therapy administration safety standards and uses InterQual tools for level-of-care determinations and case-by-case reviews.

Citation	Key finding
Tirtei et al. 2024
Retrospective multicenter cohort: outpatient administration of high-dose ifosfamide feasible with manageable toxicity in selected patients (26 pts).
Nelles et al. 2023
Retrospective cohort: DA-EPOCH-R can be delivered primarily outpatient but may require admission for complications; CR 69% in 13 patients.
Banh et al. 2021
Single-center review: outpatient ifosfamide feasible with cost savings but higher severe hematologic events in IP group; 86 patients.
Li et al. 2020
Single-center review: 219 cycles of DA-EPOCH, 193 outpatient cycles; no hospitalizations during outpatient administration.
ASCO-ONS Standards 2024
Updated safety standards and responsibilities for antineoplastic therapy administration including outpatient/home settings.

TACE (Transcatheter Arterial Chemoembolization): a procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor (NCI, 2022).

Revision History

2026-05-01material_changeLatest

Summary of Changes dated 05/01/2026 notes removal of exclusion for individuals under 18; supporting information and clinical evidence updated; previous version archived as CS198ID.A. Removed language indicating this policy does not apply to individuals under 18 years of age.

2026-05-01non-material_update

Multiple recent studies and ASCO-ONS 2024 standards were added/updated in Clinical Evidence. Updated Clinical Evidence and References sections to reflect current information.